• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

多吉美联合特罗凯_P2试验失败

[复制链接]
3270 2 lostm 发表于 2012-9-20 21:36:42 | 查看全部 | 阅读模式 来自: 上海

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
胆管癌。
22/32 在4个月内进展或死亡。
总体生存期6月
剂量,每天多吉美400mg*2,特罗凯100mg. 毒性可耐受。

SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.  Print this page  


Sub-category:
Hepatobiliary Cancer


Category:
Gastrointestinal (Noncolorectal) Cancer


Meeting:
2012 ASCO Annual Meeting


Session Type and Session Title:
General Poster Session, Gastrointestinal (Noncolorectal) Cancer


Abstract No:
4113


Citation:
J Clin Oncol 30, 2012 (suppl; abstr 4113)


Author(s):
Anthony B. El-Khoueiry, Cathryn J Rankin, Syma Iqbal, Kenneth C. Micetich, Omar Kayaleh, Heinz-Josef Lenz, C. D. Blanke; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; Loyola University Medical Center, Maywood, IL; M. D. Anderson Cancer Center Orlando, Orlando, FL; University of British Columbia/British Columbia Cancer Agency, Vancouver, BC, Canada



Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

Abstract:

Background: The treatment of pts with advanced biliary cancers represents a therapeutic challenge. The vascular endothelial growth factor and epidermal growth factor receptor pathways play an important role in biliary carcinogenesis, as evidenced by their up-regulation and prognostic impact. Methods: The primary objective was progression free survival (PFS) (improvement in PFS from 4 to 8 months); secondary endpoints included overall survival (OS), objective response rate, and toxicity. A two-stage design was used; if 13 or more eligible pts of the 25 initially accrued were alive without progression at 4 months, an additional 25 were to be accrued. Eligibility criteria included no prior treatment for advanced or metastatic disease, histologic diagnosis of gallbladder cancer or cholangiocarcinoma, presence of measurable disease, Zubrod performance status 0-1, AST/ALT ≤ 5 IULN, total bilirubin ≤1.5 IULN, adequate hematologic function. Pts were treated with sorafenib 400 mg PO BID and erlotinib 100 mg PO q daily continuously. Restaging scans were performed every 8 weeks. Results: 32 eligible pts were accrued. 30 pts were evaluable for response. 2 patients (7 %) had an unconfirmed partial response (95% CI:1%-23%), and 8 pts (27%) had stable disease. Median PFS was 2 months (95% CI: 2-3 months). 22/32 patients progressed or died within 4 months of registration. Median OS was 6 months (95% CI: 3 -7 months). The study failed to meet its primary endpoint to proceed to the second stage of accrual. There were 3 deaths on study, 1 of which was possibly related to treatment. 19 patients (59%) had grade 3 or 4 toxicities: AST/ALT (22%), bilirubin (16%), alkaline phosphatase (16%), hypertension (16%), diarrhea (9%), hepatic infection (6%). Conclusions: This multicenter study was the first to evaluate the combination of sorafenib and erlotinib in pts with advanced biliary cancers. Despite manageable toxicity, the study failed to meet its primary endpoint. Correlative studies on collected tissue and blood are ongoing; improved pt selection based on tumor biology and molecular markers is necessary for future evaluation of targeted therapies in this disease.



2条精彩回复,最后回复于 2012-10-8 22:55

gprs111  初中一年级 发表于 2012-10-8 22:21:23 | 显示全部楼层 来自: 湖北武汉
特罗凯单药如何?

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表